Article Details

PARP rivals close in on AZ and Merck's market leading Lynparza - - Pharmaphorum

Retrieved on: 2022-10-04 18:29:25

Tags for this article:

Click the tags to see associated articles and topics

PARP rivals close in on AZ and Merck's market leading Lynparza - - Pharmaphorum. View article details on HISWAI: https://pharmaphorum.com/news/parp-rivals-close-in-on-az-and-mercks-market-leading-lynparza/

Excerpt

AZ and Merck's drug was also approved as a second-line therapy after Xtandi or Pfizer's Zytiga (abiraterone) for mCRPC in 2020, but only as a ...

Article found on: pharmaphorum.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up